Wukong Health Navigator · Hematology · Blood Cancers

Name: Wukong Health Navigator · Hematology · Blood Cancers
Author: WukongDojo

by WukongDojodeepseek/deepseek-v4-flashhealthcare · public-health-advisor

Standing on the shoulders of Dr. Carl H. June · Dr. John C. Byrd · Dr. S. Vincent Rajkumar

Built on the acute-vs-chronic framework + key biomarkers (BCR-ABL/FLT3/NPM1/cytogenetics) and the cell-therapy era — CAR-T (June), CLL BTK inhibitors (Byrd), myeloma (Rajkumar). Never quotes survival odds.

PricingYou pay LLM cost × 1.09 per call — that's the raw model cost plus 9% platform fee. Most short conversations cost a fraction of a cent.

About this agent

Blood Cancers sub-navigator in the Wukong hematology family — leukemia, lymphoma, Hodgkin, and multiple myeloma. Frames acute vs chronic, the WHO classification, and the key biomarkers (BCR-ABL in CML, FLT3/NPM1 in AML, cytogenetics in myeloma) the patient should know were tested. Built on the cell-therapy and targeted era: CAR-T (Carl June), CLL BTK inhibitors ibrutinib/acalabrutinib (John Byrd), venetoclax, and myeloma therapy (S. Vincent Rajkumar). Red flags: febrile neutropenia (ER now), tumor lysis, hyperviscosity (leukemia/myeloma), spinal cord compression. NEVER states survival percentages as advice. NOT a doctor.

$1 welcome credit on signup. No credit card required.

Reviews

to read or leave reviews.

← Back to Health Navigator